Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Pfizer License Agreement Convertible Preferred Stock	Common Stock	Additional paid-in capital	Accumulated deficit
Beginning balance at Dec. 31, 2020		$ 21,942
Beginning Balance, Shares at Dec. 31, 2020		22,724,925
Beginning balance at Dec. 31, 2020	$ (15,645)			$ 1	$ 97	$ (15,743)
Beginning Balance, Shares at Dec. 31, 2020				1,289,342
Issuance of Series B convertible preferred stock		$ 152,081	$ 20,000
Issuance of Series B convertible preferred stock, Shares		92,660,103	12,152,145
Stock options exercised	14				14
Stock options exercised (Shares)				16,370
Vesting of restricted common stock	9			$ 1	8
Vesting of restricted common stock (Shares)				333,888
Stock-based compensation	3,329				3,329
Net loss	(59,146)					(59,146)
Ending balance at Sep. 30, 2021		$ 194,023
Ending balance (in shares) at Sep. 30, 2021		127,537,173
Ending balance at Sep. 30, 2021	(71,439)			$ 2	3,448	(74,889)
Ending balance (in shares) at Sep. 30, 2021				1,639,600
Beginning balance at Jun. 30, 2021		$ 194,023
Beginning Balance, Shares at Jun. 30, 2021		127,537,173
Beginning balance at Jun. 30, 2021	(57,588)			$ 2	3,124	(60,714)
Beginning Balance, Shares at Jun. 30, 2021				1,519,007
Stock options exercised	3				3
Stock options exercised (Shares)				104,223
Vesting of restricted common stock	14				14
Vesting of restricted common stock (Shares)				16,370
Stock-based compensation	307				307
Net loss	(14,175)					(14,175)
Ending balance at Sep. 30, 2021		$ 194,023
Ending balance (in shares) at Sep. 30, 2021		127,537,173
Ending balance at Sep. 30, 2021	(71,439)			$ 2	3,448	(74,889)
Ending balance (in shares) at Sep. 30, 2021				1,639,600
Beginning balance at Dec. 31, 2021	261,313			$ 32	352,999	(91,718)
Beginning Balance, Shares at Dec. 31, 2021				32,222,881
Stock options exercised	$ 183				183
Stock options exercised (Shares)	73,841			73,841
Vesting of restricted common stock	$ 1				1
Vesting of restricted common stock (Shares)				291,418
Stock-based compensation	11,866				11,866
Net loss	(84,616)					(84,616)
Ending balance at Sep. 30, 2022	188,747			$ 32	365,049	(176,334)
Ending balance (in shares) at Sep. 30, 2022				32,588,140
Beginning balance at Jun. 30, 2022	211,966			$ 32	360,594	(148,660)
Beginning Balance, Shares at Jun. 30, 2022				32,483,883
Stock options exercised	6				6
Stock options exercised (Shares)				9,003
Vesting of restricted common stock (Shares)				95,254
Stock-based compensation	4,449				4,449
Net loss	(27,674)					(27,674)
Ending balance at Sep. 30, 2022	$ 188,747			$ 32	$ 365,049	$ (176,334)
Ending balance (in shares) at Sep. 30, 2022				32,588,140